Russell M. Hagan - Concepedia

Author

Russell M. Hagan

University of Hertfordshire

Also Known As

Julian Golec, RUSSELL M. HAGAN, Russell Hagan, Russell M Hagan, Russell M. Hagan

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

University of Hertfordshire GlaxoSmithKline (United Kingdom)Tokyo Medical and Dental University

About

Russell M. Hagan is an author at University of Hertfordshire specializing in medicine, neuropharmacology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	633
2	Social Sciences	6	6	325
3	Biochemistry	2	2	31
4	Health Sciences	1	1	130
5	Endocrinology	1	1	56

Russell M. Hagan

Publications

777

Citations

H-Index

Page 1

	Year	Citations
Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats Eric Southam, D.L. Kirkby, Guy A. Higgins, European Journal of Pharmacology Psychoactive DrugPharmacological StudyMedicinePhysiologyMonoamine Uptake	1998	130
Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain Russell M. Hagan, A. W. Butler, Julia M. Hill, European Journal of Pharmacology NeurophysiologyNeuroanatomyMedicineNeuropeptide ReceptorNeuropharmacology	1987	114
Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model Sharon C. Stratton, Charles H. Large, Brian J. Cox, Epilepsy Research Seizure DevelopmentRat AmygdalaPsychiatryNeurophysiologyNeuroanatomy	2003	91
Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor Andrew B. McElroy, Stephen P. Clegg, Martyn J. Deal, Journal of Medicinal Chemistry	1992	74
Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat Paul G. Overton, Peter J. Elliott, Russell M. Hagan, European Journal of Pharmacology Molecular PharmacologyMolecular NeuroscienceAffect A9MedicinePhysiology	1992	56
Development of Tolerance in Mice to the Sedative Effects of the Neuroactive Steroid Minaxolone Following Chronic Exposure Fiona H. Marshall, Sharon C. Stratton, Joanne Mullings, Pharmacology Biochemistry and Behavior MedicinePharmacologyNeuropharmacologyToxicologyNeuroprotection	1997	56
GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors I.J.M. Beresford, R.L.G. Sheldrick, Douglas I. Ball, European Journal of Pharmacology Molecular PharmacologyMedicineImmunologyNeuropeptide ReceptorPotent Non-peptide Antagonist	1995	49
Modulation of the rat mesolimbic dopamine pathway by neurokinins Peter J. Elliott, G.S. Mason, Elizabeth Graham, Behavioural Brain Research NeurophysiologyPhysiologyNeuropharmacologyNeuroscienceNervous System	1992	35
Conformationally constrained tachykinin analogs: potent and highly selective neurokinin NK-2 receptor agonists Martyn J. Deal, Russell M. Hagan, S.J. Ireland, Journal of Medicinal Chemistry	1992	33
Benserazide and carbidopa as substrates of catechol-O-methyltransferase: New mechanism of action in Parkinson's disease Russell M. Hagan, Michael J. Raxworthy, Peter A. Gulliver Biochemical Pharmacology Medicinal ChemistryMedicineParkinson DiseaseNew MechanismNeuropharmacology	1980	26

Page 1